Please login to the form below

Not currently logged in
Email:
Password:

UCB reports H1 profit rise

UCB's profit has been boosted by increased sales of core drugs

UCB, the Belgian pharmaceutical company, has posted an 11 per cent increase in pre-tax profit to €443m for the first six months of 2011, reflecting a strong increase in sales.

The company's total revenue for the period increased by 2 per cent to €1.68bn. It reported significant sales growth of new medicines Cimzia (certolizumab pegol - 72 per cent), Vimpat (lacosamide - 76 per cent) and Neupro (rotigotine - 17 per cent). UCB also noted a strong performance of its anti-epileptic drug Keppra (levetiracetam) in Europe and Japan.

Roch Doliveux, CEO, said: "We are excited about the momentum of Cimzia, Vimpat and Neupro, about the potential UCB new medicines from our promising pipeline and about the fact that from 2012 onward, we will have a decade without impacts from major patent expiries."

The company's pipeline has been strengthened with positive phase III results for Cimzia in rheumatoid arthritis and Neupro for advanced Parkinson's disease.

29th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics